Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes

Lauren E. Cain(Harvard University), Miguel A. Hernán(Harvard University), Vasilis Paparizos(Harvard University), Roberto Muga, Rafael Rubio(Research Institute Hospital 12 de Octubre), Jonathan A C Sterne(University of Bristol), Heiner C. Bucher(University of Basel), Amy C. Justice(Yale University), Ashley Olson(MRC Human Nutrition Research), Anna Esteve(Harvard University), Dominique Costagliola(Inserm), Inmaculada Jarrín(Instituto de Salud Carlos III), Ellen C. Caniglia(Botswana Harvard AIDS Institute Partnership), Sophie José(NHS England), Giota Touloumi(National and Kapodistrian University of Athens), Jan Fehr(University Hospital of Zurich), James M. Robins(Harvard University), Caroline Sabin(Primary Health Care), Laurence Meyer(Université Paris-Sud), Janet P. Tate, Santiago Pérez‐Hoyos(Vall d'Hebron Hospital Universitari), Ard van Sighem(Stichting HIV Monitoring), Andrew Phillips(University College London), Marie-Anne Vandenhende(Université de Bordeaux), Sophie Abgrall(Inserm), François Dabis(Université de Bordeaux), Jordi Casabona(Universitat Autònoma de Barcelona), Roger Logan(Harvard University), Rémonie Seng(Université Paris-Sud), Peter Reiss(Amsterdam Institute for Global Health and Development)
Medicine
October 1, 2016
Cited by 3


Related Papers